Business
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study
About this update from Precision Biosciences, Inc.
[{"type":"text","content":"\nPrecision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will host an investor webcast to discuss new biopsy and clinical data from the ongoing Phase 1 ELIMINATE-B trial. The presentation will include new clinical data along with late-breaker biopsy data featured at the European Association for the Study of the Liver (EASL) Congress 2026 on May 27, 2026, in Barcelona, Spain. A news release with details of the clinical data will be available here after the conference embargo lifts on May 27, 2026. The ELIMINATE-B trial is evaluating PBGENE-HBV for the treatment of chronic hepatitis B.\n\n\nThe investor webcast will include Company management and Hepatitis B experts and will be held on May 27th, 2026, at 8:00 AM EDT. Pre-registration for the event can be found here.\n\n\nA replay of the webcast will be available on the Investors section of the Company's website at investor.precisionbiosciences.com following the event.\n\n\nAbout PBGENE-HBV, A Viral Elimination Program\nPBGENE-HBV is Precision’s wholly owned in vivo gene editing program under investigation in a global first-in-human clinical trial, which is designed to be a potentially curative treatment for chronic hepatitis B infection. PBGENE-HBV is the first and only potentially curative gene editing program to enter the clinic that is specifically designed to eliminate the root cause of chronic hepatitis B, cccDNA. Elimination of cccDNA results in HBV viral cure as cccDNA is the only source of infectious replication (HBV DNA). The ELIMINATE-B trial is investigating PBGENE-HBV at multiple dose levels across a number of administrations per dose level in patients with chronic hepatitis B. PBGENE-HBV has been granted Fast Track designation by the FDA.\n\n\nPBGENE-HBV is the only clinical stage program directly targeting the elimination of cccDNA leading to sustained loss of HBV DNA. The FDA has previously provided guidance that sustained loss of HBV DNA is an approvable endpoint for chronic hepatitis B.\n\n\nFurther details on the trial can be found on Precision’s website and on clinicaltrials.gov identifier NCT06680232.\n\n\nAbout Precision BioSciences, Inc.\nPrecision BioSciences, Inc. is a clinical stage gene ...